Jeffrey S. Ross
YOU?
Author Swipe
View article: Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer Open
Background: Immune checkpoint inhibitors (ICIs) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite insta…
View article: A Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia
A Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia Open
Background/Objectives: This study investigates genomic alterations (GA) between NPM1-mutated (NPM1mut) and wild-type (NPM1wt) acute myeloid leukemia (AML), aiming to better understand the AML genomic profile. NPM1mut AML represents a disti…
View article: Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization
Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization Open
In the context of cancer, whether or not to choose pregnancy termination represents a difficult and multifaceted decision. In this editorial, members of The Oncologist editorial team attempt to contextualize the potential implications of t…
View article: <scp>AXL</scp> and <scp>SRC</scp> in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis
<span>AXL</span> and <span>SRC</span> in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis Open
Novel treatment options for metastatic renal cell carcinomas (RCC) include specific MET inhibitors, GAS6/AXL inhibitors, and SRC inhibitors. The interplay between c‐MET, SRC, AXL expression, and their gene mutation patterns in different re…
View article: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types Open
Background There is uncertainty around clinical applicability of tumor mutational burden (TMB) across cancer types, in part because of inconsistency between TMB measurements from different platforms. The KEYNOTE 158 trial supported United …
View article: <i>KMT2A</i> (<i>MLL1</i>) Rearrangements in Hematolymphoid Malignancies: A Genomic Landscape Study
<i>KMT2A</i> (<i>MLL1</i>) Rearrangements in Hematolymphoid Malignancies: A Genomic Landscape Study Open
Background: KMT2A (MLL1) gene is altered in a variety of hematolymphoid neoplasms and solid tumors. In acute myelocytic leukemia, the interactions between KMT2A gene fusion proteins and menin have been linked to leukemogenesis and represen…
View article: Artificial Intelligence–Generated Editorials in Radiology: Can Expert Editors Detect Them?
Artificial Intelligence–Generated Editorials in Radiology: Can Expert Editors Detect Them? Open
GPT-4 can write high-quality articles that iThenticate does not flag as plagiarized, which may go undetected by editors, and that detection tools can detect to a limited extent. Editors showed a positive bias toward human-written articles.
View article: Age and Sex Affects the Frequency and Mutation Type of <i>FGFR2</i> Alterations in Cholangiocarcinoma
Age and Sex Affects the Frequency and Mutation Type of <i>FGFR2</i> Alterations in Cholangiocarcinoma Open
PURPOSE FGFR2 alterations are infrequent but currently represent the most common targetable mutation in cholangiocarcinoma. We performed a large-scale genomic analysis to assess associations between FGFR2 and other driver gene alterations …
View article: Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities
Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities Open
Background Malignant phyllodes tumors (MPT) are rare fibroepithelial breast cancers with no known effective systemic therapy; metastatic progression portends a dismal prognosis. We sought to describe the genomic landscape of MPTs through g…
View article: Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study Open
F Hoffmann-La Roche.
View article: <i>KRAS</i> Allelic Variants in Biliary Tract Cancers
<i>KRAS</i> Allelic Variants in Biliary Tract Cancers Open
Importance Biliary tract cancers (BTCs) contain several actionable molecular alterations, including FGFR2 , IDH1 , ERBB2 (formerly HER2 ), and KRAS . KRAS allelic variants are found in 20% to 30% of BTCs, and multiple KRAS inhibitors are c…
View article: Anatomic Subtype Differences in Extramammary Paget Disease
Anatomic Subtype Differences in Extramammary Paget Disease Open
Importance Extramammary Paget disease (EMPD) is a rare, highly recurrent cutaneous malignant neoplasm of unclear origin. EMPD arises most commonly on the vulvar and penoscrotal skin. It is not presently known how anatomic subtype of EMPD a…
View article: Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers
Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers Open
Background While many molecular assays can detect mutations at low tumor purity and variant allele frequencies, complex biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and genomic loss of heterozygosity …
View article: Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer
Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer Open
Background: Advanced urothelial cancer (aUC) is often characterized by rapid symptomatic disease progression, making early disease control of particular importance. Circulating tumor DNA (ctDNA) is a promising prognostic biomarker and emer…
View article: Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma
Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma Open
Myxofibrosarcoma (MFS) is a common soft tissue sarcoma of the elderly that typically shows low tumor mutational burden, with mutations in TP53 and in genes associated with cell cycle checkpoints ( RB1 , CDKN2A ). Unfortunately, no alterati…
View article: Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers Open
Background One of the most common sporadic homozygous deletions in cancers is 9p21 loss, which includes the genes methylthioadenosine phosphorylase (MTAP), CDKN2A, and CDKN2B, and has been correlated with worsened outcomes and immunotherap…
View article: Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden
Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden Open
Importance Tumor mutational burden (TMB) is a putative biomarker of efficacy for immune checkpoint inhibitor (ICI) therapies of solid tumors, but not specifically for penile squamous cell carcinoma (PSCC). Objective To characterize biomark…
View article: Data from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Data from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Purpose:BRAF mutations are rare in biliary tract cancers (BTC), but are of interest given the recent developments in targeted therapy for BTC. We investigated the clinical outcomes in a cohort of BRAF-mutant advanced BTC treated with first…
View article: Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Figure S1: Progression Free Survival separated out by individual mutation classes
View article: Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Figure S1: Progression Free Survival separated out by individual mutation classes
View article: Supplementary Table S4 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S4 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S4: OS Cox Regression with Univariate, Full Multivariate, and Explanatory Multivariate Analysis
View article: Supplementary Figure S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Figure S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Figure S2: Overall Survival separated out by individual mutation classes.
View article: Supplementary Table S5 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S5 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S5: Early Phase Clinical Trials of BRAF Dimer Inhibitors or Breakers
View article: Supplementary Table S3 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S3 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S3: PFS Cox Regression with Univariate, Full Multivariate, and Explanatory Multivariate Analysis
View article: Supplementary Table S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S2: Categorical Variables Used for the Comparative Genomics Analyses
View article: Supplementary Table S3 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S3 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S3: PFS Cox Regression with Univariate, Full Multivariate, and Explanatory Multivariate Analysis